ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-17	0.000100 $	+900.00%	10,510
26-06-15	0.000010 $	-90.00%	285
26-06-12	0.000100 $	0.00%	605
26-06-11	0.000100 $	0.00%	100
26-06-10	0.000100 $	0.00%	1,517

Delayed Quote OTC Markets

More quotes

Delayed OTC Markets Other stock markets 12:21:48 2026-06-17 EDT			5-day change	1st Jan Change
0.000100 ^USD	+900.00%		0.00%	-

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.54M 3.25M 3.06M 5.75M 387M 5.8M 38.55M 15.01M 190M 15.39M 15.06M 657M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.12M -1.03M -967K -1.82M -122M -1.83M -12.18M -4.74M -60.02M -4.86M -4.76M -208M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
23-04-11	Insider Buy: Obseva	MT
23-04-05	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
23-03-31	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-30	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
23-03-22	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
23-03-15	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
23-03-13	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
23-03-13	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
23-03-13	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
23-03-13	ObsEva SA Announces Executive Changes	CI
23-03-03	Top Premarket Gainers	MT

22-08-30	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
22-08-01	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
22-07-29	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
22-06-03	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
22-04-26	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-03-31	ObsEva Files Year End 2022 Financial Statements	GL
23-03-22	OBSEVA SA : Other Events (form 8-K)	AQ
23-03-15	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

23-04-20	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
23-04-06	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
23-04-06	Bourse Zurich: ouverture en hausse avant le long week-end pascal
23-03-31	Obseva bleibt 2022 tief in den roten Zahlen
23-03-31	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.58
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-04-05	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23-02-27	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23-02-22	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	+900.00%	0.00%	0.00%	-99.83%	1.17K
ARGENX SE	+3.23%	+2.25%	+65.02%	+116.66%	54.54B
WUXI APPTEC CO., LTD.	+0.04%	+5.05%	+43.44%	+36.75%	43.86B
BIONTECH SE	+2.13%	+6.17%	-12.87%	-16.80%	22.63B
INSMED INCORPORATED	+2.59%	+6.43%	-2.49%	+383.84%	20.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.53%	-0.27%	+12.68%	-37.07%	15.84B
GENMAB A/S	+5.27%	+1.87%	+13.67%	-38.00%	14.83B
EXELIXIS, INC.	+0.85%	-0.44%	+26.59%	+176.40%	13.1B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.17%	+4.13%	+13.12%	-	12.66B
MADRIGAL PHARMACEUTICALS, INC.	+0.30%	+5.73%	+78.22%	+103.00%	11.56B
Average	+90.87%	-8.84%	+23.74%	+69.44%	20.97B
Weighted average by Cap.	+1.42%	+0.18%	+33.05%	+90.79%

	2021	2022
Net sales	-	19.64M 16.94M 15.58M 14.66M 27.55M 1.85B 27.78M 185M 71.86M 910M 73.7M 72.13M 3.15B
Net income	-58.38M -50.36M -46.3M -43.58M -81.89M -5.51B -82.58M -549M -214M -2.7B -219M -214M -9.35B	-29.88M -25.78M -23.7M -22.31M -41.91M -2.82B -42.27M -281M -109M -1.38B -112M -110M -4.79B
Net Debt	-28.08M -24.22M -22.27M -20.96M -39.38M -2.65B -39.71M -264M -103M -1.3B -105M -103M -4.5B	-5.4M -4.66M -4.28M -4.03M -7.57M -509M -7.63M -50.73M -19.75M -250M -20.26M -19.82M -865M